Literature DB >> 18626802

Contrast agents: magnetic resonance.

Carmen Burtea1, Sophie Laurent, Luce Vander Elst, Robert N Muller.   

Abstract

Even though the intrinsic magnetic resonance imaging (MRI) contrast is much more flexible than in other clinical imaging techniques, the diagnosis of several pathologies requires the involvement of contrast agents (CAs) that can enhance the difference between normal and diseased tissues by modifying their intrinsic parameters. MR CAs are indirect agents because they do not become visible by themselves as opposed to other imaging modalities. The signal enhancement produced by MRI CAs (i.e., the efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) relaxivity (expressed in s(-1) mmol(-1) 1), which is defined as the increase of the nuclear relaxation rate (the reciprocal of the relaxation time) of water protons produced by 1 mmol per liter of CA. Paramagnetic CAs (most of them complexes of gadolinium) are frequently used in clinics as extracellular, hepatobiliary or blood pool agents. Low molecular weight paramagnetic CAs have similar effects on R1 and R2, but the predominant effect at low doses is that of T1 shortening (and R1 enhancement). Thus, organs taking up such agents will become bright in a T1-weighted MRI sequence; these CAs are thus called positive contrast media. The CAs known as negative agents influence signal intensity mainly by shortening T2* and T2, which produces the darkening of the contrast-enhanced tissue. These CAs are generally composed of superparamagnetic nanoparticles, consisting of iron oxides (magnetite, Fe3O4, maghemite, gammaFe2O3, or other ferrites). Iron oxide nanoparticles are taken up by the monocyte-macrophage system, which explains their potential application as MRI markers of inflammatory and degenerative disorders. Most of the contemporary MRI CAs approved for clinical applications are non-specific for a particular pathology and report exclusively on the anatomy and the physiological status of various organs. A new generation of MRI CAs is progressively emerging in the current context of molecular imaging, agents that are designed to detect with a high specificity the cellular and molecular hallmarks of various pathologies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626802     DOI: 10.1007/978-3-540-72718-7_7

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  20 in total

Review 1.  Using Nanoparticles in Medicine for Liver Cancer Imaging.

Authors:  Farideh Farokhi Moghadam
Journal:  Oman Med J       Date:  2017-07

Review 2.  Whole animal imaging.

Authors:  Gurpreet Singh Sandhu; Luis Solorio; Ann-Marie Broome; Nicolas Salem; Jeff Kolthammer; Tejas Shah; Chris Flask; Jeffrey L Duerk
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Jul-Aug

Review 3.  Strategies for the development of gadolinium-based 'q'-activatable MRI contrast agents.

Authors:  Chuqiao Tu; Angelique Y Louie
Journal:  NMR Biomed       Date:  2012-09-27       Impact factor: 4.044

4.  Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRI.

Authors:  Jamie K Harrington; Halima Chahboune; Jason M Criscione; Alice Y Li; Narutoshi Hibino; Tai Yi; Gustavo A Villalona; Serge Kobsa; Dane Meijas; Daniel R Duncan; Lesley Devine; Xenophon Papademetri; Toshiharu Shin'oka; Tarek M Fahmy; Christopher K Breuer
Journal:  FASEB J       Date:  2011-08-16       Impact factor: 5.191

Review 5.  Nanoformulations for molecular MRI.

Authors:  Chuqiao Tu; Angelique Y Louie
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-04-06

6.  Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions.

Authors:  Sophie Emond; Francis Brunelle
Journal:  Pediatr Radiol       Date:  2011-07-24

7.  Interplay between longitudinal and transverse contrasts in Fe3O4 nanoplates with (111) exposed surfaces.

Authors:  Zijian Zhou; Zhenghuan Zhao; Hui Zhang; Zhenyu Wang; Xiaoyuan Chen; Ruifang Wang; Zhong Chen; Jinhao Gao
Journal:  ACS Nano       Date:  2014-08-26       Impact factor: 15.881

Review 8.  Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.

Authors:  Shreya Goel; Christopher G England; Feng Chen; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2016-08-09       Impact factor: 15.470

9.  Regional convection-enhanced delivery of gadolinium-labeled albumin in the rat hippocampus in vivo.

Authors:  Garrett W Astary; Svetlana Kantorovich; Paul R Carney; Thomas H Mareci; Malisa Sarntinoranont
Journal:  J Neurosci Methods       Date:  2010-01-11       Impact factor: 2.390

10.  Use of magnetic nanoparticles to monitor alginate-encapsulated betaTC-tet cells.

Authors:  Ioannis Constantinidis; Samuel C Grant; Nicholas E Simpson; Jose A Oca-Cossio; Carol A Sweeney; Hui Mao; Stephen J Blackband; Athanassios Sambanis
Journal:  Magn Reson Med       Date:  2009-02       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.